Up-to-date List of Sotalol Medical Research Studies
What Research is Being Done?
A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.
Drug: BMS-919373; Drug: Sotalol; Drug: Placebo for BMS-919373
The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker; The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests; Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline; Safety assessments based on Atrioventricular interval (AVI) and change from baseline; Safety assessments based on Wenckebach cycle length (WCL) and change from baseline; Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline
Procedure: Catheter ablation of persistent atrial fibrillation; Drug: Medical treatment alone
Difference in ejection fraction between groups; Difference in peak VO2 between groups; Difference in NYHA class between groups; Difference in BNP between groups; Difference in Quality of Life between groups; Reduction in end systolic volume; Difference in heart failure symptoms
Time in minutes until conversion to sinus rhythm (measured from the start of the first study drug administration); Conversion rate to sinus rhythm within 90 minutes (measured from the start of the first study drug administration)
Change from baseline Recurrence of Atrial Fibrillation; Change from baseline Cardiovascular hospitalisation; Change from baseline AV node ablation and catheter ablation for Atrial Fibrillation; Change from baseline Progression to permanent Atrial Fibrillation; Change from baseline Clinical progression to heart failure and left ventricular systolic dysfunction; Change from baseline Congestive heart failure; Change from baseline Interstitial pulmonary disease; Change from baseline Liver injury/toxicity; Change from baseline Renal insufficiency/failure; Change from baseline Cerebrovascular accident/Stroke; Change from baseline Myocardial infarction; Change from baseline Torsade de pointes; Death
Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.; LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality; Total mortality or cardiovascular hospitalization; Cardiovascular death; Cardiovascular death or disabling stroke; Arrhythmic death or cardiac arrest; Heart failure death; Freedom from recurrent AF; Cardiovascular hospitalization; Medical costs, resource utilization, and cost effectiveness; Quality of Life; Composite adverse events; Left atrial size, morphology and function and its relationship to morbidity and mortality
These studies may lead to new treatments and are adding insight into Sotalol etiology and treatment.
A major focus of Sotalol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.